Qasim Jaffri, DO
Psychiatry · Buffalo, NYNPI 1447469416
Payments from drug & device makers
Across 426 payments — averaging $23.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Vanda Pharmaceuticals Inc.$1K
- AbbVie$1K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$877
- Neurocrine Biosciences, Inc.$701
- plus $3K from 23 others
What the payments were for
- Food & beverage$9,779100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 57 | $1,414 |
| Vanda Pharmaceuticals Inc. | 57 | $1,300 |
| AbbVie(2 entities) | 48 | $1,129 |
| Alkermes, Inc. | 35 | $1,014 |
| Teva Pharmaceuticals USA, Inc. | 30 | $877 |
| Neurocrine Biosciences, Inc. | 31 | $701 |
| Lundbeck LLC | 27 | $597 |
| Johnson & Johnson | 39 | $584 |
| Sunovion Pharmaceuticals Inc. | 23 | $421 |
| Otsuka America Pharmaceutical, Inc. | 20 | $399 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $251 |
| Axsome Therapeutics, Inc. | 8 | $236 |
| E.r. Squibb & Sons, L.L.C. | 5 | $210 |
| Livanova USA, Inc. | 3 | $98 |
| Bausch Health US, LLC | 4 | $75 |
| Eisai Inc. | 4 | $67 |
| Indivior Inc. | 3 | $67 |
| Almatica Pharma LLC | 3 | $63 |
| Orexo US, Inc. | 2 | $44 |
| Idorsia Pharmaceuticals US Inc | 2 | $38 |
| Noven Therapeutics, LLC | 2 | $37 |
| Acadia Pharmaceuticals Inc | 2 | $31 |
| Biogen | 1 | $28 |
| Alfasigma USA, Inc. | 2 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $22 |
| Neos Therapeutics, LP | 1 | $18 |
| Merck | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Neuronetics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$944
- ARISTADA INITIO$236
- VRAYLAR$125
- UZEDY$125
- Austedo XR$125
- CAPLYTA$125
- COBENFY$118
How this compares
$9,796 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $88,938 |
| NuplazidPimavanserin Tartrate | 13 | $74,374 |
| RexultiBrexpiprazole | 42 | $69,620 |
| FanaptIloperidone | 14 | $28,373 |
| TrintellixVortioxetine Hydrobromide | 35 | $22,702 |
| AuvelityDextromethorphan Hbr/Bupropion | 13 | $18,493 |
| Asenapine Maleate | 22 | $6,487 |
| Clonazepam | 324 | $5,554 |
| Bupropion XlBupropion Hcl | 182 | $4,474 |
| Quetiapine Fumarate | 138 | $4,342 |
| Divalproex Sodium ErDivalproex Sodium | 44 | $3,845 |
| Clozapine | 29 | $2,715 |
| Duloxetine Hcl | 162 | $2,714 |
| Vilazodone Hcl | 24 | $2,632 |
| Fluoxetine Hcl | 100 | $2,156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $701 | $88,93811 claims |
| Acadia Pharmaceuticals IncNuplazid | $31 | $74,37413 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $399 | $69,62042 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,300 | $28,37314 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $251 | $22,70235 claims |
| Axsome Therapeutics, Inc.Auvelity | $236 | $18,49313 claims |
| Almatica Pharma LLCSertraline Hcl | $63 | $1,646106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Buffalo
- Subhdeep VirkBuffalo$3M
- Steven DubovskyBuffalo$422K
- Wendy WeinsteinBuffalo$388K
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.